TY - JOUR
T1 - Use of optical coherence tomography in the care of people with multiple sclerosis in Switzerland
T2 - A national survey among neurologists
AU - Kana, Veronika
AU - Herwerth, Marina
AU - Gugleta, Konstantin
AU - Bernard-Valnet, Raphaël
AU - Mueller, Stefanie
AU - Mallucci, Giulia
AU - Fierz, Fabienne C.
AU - Granziera, Cristina
AU - Kuhle, Jens
AU - Roth, Patrick
AU - Papadopoulou, Athina
N1 - Publisher Copyright:
© The Author(s), 2026. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PY - 2026/1/1
Y1 - 2026/1/1
N2 - Background: Optical coherence tomography (OCT) can assess optic nerve involvement and facilitate the diagnosis of multiple sclerosis (MS). Objective: To evaluate the current use of OCT for MS care among neurologists in Switzerland. Methods: Nationwide online survey with Swiss neurologists, comprising 11 questions on availability, use of OCT, and its role in diagnostic workup and monitoring. Results: Thirty-four neurologists from all main Swiss regions responded (53% hospital-based, 47% private practice). Only 26.5% had access to OCT in their clinic/practice, all of whom were MS specialists, mainly hospital-based (66.7%). All respondents assess the visual pathway in first demyelinating event and optic neuritis (ON), primarily using magnetic resonance imaging (MRI: 88.2% and 91.2%, respectively), often in combination with visual evoked potentials (VEP). OCT use was reported by 32% (first demyelinating event) and 44% (ON) of respondents. OCT was infrequently used for monitoring (20.6%), the most frequent reasons being “lack of availability” or “insufficient evidence.” Conclusions: Despite the scientific evidence, OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in MS care are needed, while ongoing real-world research should shed more light into its role for personalized disease monitoring in people with MS.
AB - Background: Optical coherence tomography (OCT) can assess optic nerve involvement and facilitate the diagnosis of multiple sclerosis (MS). Objective: To evaluate the current use of OCT for MS care among neurologists in Switzerland. Methods: Nationwide online survey with Swiss neurologists, comprising 11 questions on availability, use of OCT, and its role in diagnostic workup and monitoring. Results: Thirty-four neurologists from all main Swiss regions responded (53% hospital-based, 47% private practice). Only 26.5% had access to OCT in their clinic/practice, all of whom were MS specialists, mainly hospital-based (66.7%). All respondents assess the visual pathway in first demyelinating event and optic neuritis (ON), primarily using magnetic resonance imaging (MRI: 88.2% and 91.2%, respectively), often in combination with visual evoked potentials (VEP). OCT use was reported by 32% (first demyelinating event) and 44% (ON) of respondents. OCT was infrequently used for monitoring (20.6%), the most frequent reasons being “lack of availability” or “insufficient evidence.” Conclusions: Despite the scientific evidence, OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in MS care are needed, while ongoing real-world research should shed more light into its role for personalized disease monitoring in people with MS.
KW - MS
KW - McDonald diagnostic criteria
KW - OCT
KW - demyelinating event
KW - optic neuritis
UR - https://www.scopus.com/pages/publications/105031154865
U2 - 10.1177/20552173261419951
DO - 10.1177/20552173261419951
M3 - Article
AN - SCOPUS:105031154865
SN - 2055-2173
VL - 12
JO - Multiple Sclerosis Journal - Experimental, Translational and Clinical
JF - Multiple Sclerosis Journal - Experimental, Translational and Clinical
IS - 1
ER -